A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease

Author： Mölken Maureen P.M.H. Rutten-van

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.8, 2007-01, pp. : 695-711

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Roflumilast: In Chronic Obstructive Pulmonary Disease

By Sanford Mark

Drugs, Vol. 70, Iss. 12, 2010-08 ,pp. : 1615-1627

Adis International

Access to resources Recommend Favorite

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

By Lock Kevin Wilson Koo Murphy Daniel Riesco Juan Antonio

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2613-2626

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues

By Mölken Maureen P.M.H. Rutten-van Goossens Lucas M.A.

PharmacoEconomics, Vol. 30, Iss. 4, 2012-04 ,pp. : 271-302

Adis International

Access to resources Recommend Favorite

Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease

By Spencer Michael

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 619-637

Adis International

Access to resources Recommend Favorite

Roflumilast: a guide to its use in chronic obstructive pulmonary disease

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 6-10

Adis International

Access to resources Recommend Favorite